Actinogen Medical (ASX:ACW) has announced that recruitment of patients into XanADu, the phase 2 clinical trial of Xanamem in the treatment of Alzheimer’s disease, will cease on 26 October 2018.
Following this early notice of recruitment closure, the final few prospective patients should have adequate time to be included in the study, said the company.
The patients will undergo a detailed eligibility evaluation before being enrolled into XanADu.
"Final patient enrolment numbers will be announced over the coming weeks, however over-enrolment above the planned 174 patients, is likely," said the company.
"Currently 169 patients have been enrolled into XanADu.
"The high recruitment rate of patients into XanADu follows high engagement from study sites and research teams participating in this important global Alzheimer’s trial."
According to Actinogen Medical CEO Dr Bill Ketelbey, “We are delighted to have reached this important milestone in our XanADu trial with closure of recruitment.
“The eagerness and enthusiasm of patients and study site investigators to be involved in the XanADu trial is very pleasing. With over 50 million people suffering from this terrible disease globally, the need to discover additional drugs to treat Alzheimer’s has never been more urgent, and we hope that the results from our trial represent an important next step in providing an effective new therapy to patients.
"We look forward to updating the market on our next key milestone of the final patient being enrolled into XanADu, as well as announcing the results for XanADu and some of the additional Xanamem studies, in Q2 2019”.